[1]
Torre, L. A.; Bray, F.; Siegel, R. L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015, 65, 87-108.
[2]
Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D. M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in globocan 2012. Int. J. Cancer 2015, 136, E359-E386.
[3]
Fidler, M. M.; Bray, F.; Soerjomataram, I. The global cancer burden and human development: A review. Scand. J. Public Health 2018, 46, 27-36.
[4]
Nam, J.; Son, S.; Park, K. S.; Zou, W. P.; Shea, L. D.; Moon, J. J. Cancer nanomedicine for combination cancer immunotherapy. Nat. Rev. Mater. 2019, 4, 398-414.
[5]
Shi, J.; Kantoff, P. W.; Wooster, R.; Farokhzad, O. C. Cancer nanomedicine: Progress, challenges and opportunities. Nat. Rev. Cancer 2017, 17, 20-37.
[6]
Kim, K. Y. Nanotechnology platforms and physiological challenges for cancer therapeutics. Nanomedicine: Nanotechnol., Biol. Med. 2007, 3, 103-110.
[7]
Kalaydina, R. V.; Bajwa, K.; Qorri, B.; Decarlo, A.; Szewczuk, M. R. Recent advances in “smart” delivery systems for extended drug release in cancer therapy. Int. J. Nanomedicine 2018, 13, 4727-4745.
[8]
Van Der Meel, R.; Sulheim, E.; Shi, Y.; Kiessling, F.; Mulder, W. J. M.; Lammers, T. Smart cancer nanomedicine. Nat. Nanotechnol. 2019, 14, 1007-1017.
[9]
Shao, K.; Singha, S.; Clemente-Casares, X.; Tsai, S.; Yang, Y.; Santamaria, P. Nanoparticle-based immunotherapy for cancer. ACS Nano 2015, 9, 16-30.
[10]
Asadujjaman, M.; Cho, K. H.; Jang, D. J.; Kim, J. E.; Jee, J. P. Nanotechnology in the arena of cancer immunotherapy. Arch. Pharm. Res. 2020, 43, 58-79.
[11]
Helmy, K. Y.; Patel, S. A.; Nahas, G. R.; Rameshwar, P. Cancer immunotherapy: Accomplishments to date and future promise. Ther. Deliv. 2013, 4, 1307-1320.
[12]
Sun, Q. X.; Barz, M.; De Geest, B. G.; Diken, M.; Hennink, W. E.; Kiessling, F.; Lammers, T.; Shi, Y. Nanomedicine and macroscale materials in immuno-oncology. Chem. Soc. Rev. 2019, 48, 351-381.
[13]
Shi, Y.; Lammers, T. Combining nanomedicine and immunotherapy. Acc. Chem. Res. 2019, 52, 1543-1554.
[14]
Song, W. T.; Musetti, S. N.; Huang, L. Nanomaterials for cancer immunotherapy. Biomaterials 2017, 148, 16-30.
[15]
Chen, D. S.; Mellman, I. Oncology meets immunology: The cancer- immunity cycle. Immunity 2013, 39, 1-10.
[16]
Sanmamed, M. F.; Chen, L. P. A paradigm shift in cancer immunotherapy: From enhancement to normalization. Cell 2018, 175, 313-326.
[17]
Dunn, G. P.; Bruce, A. T.; Ikeda, H.; Old, L. J.; Schreiber, R. D. Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol. 2002, 3, 991-998.
[18]
Galluzzi, L.; Vacchelli, E.; Bravo-San Pedro, J. M.; Buqué, A.; Senovilla, L.; Baracco, E. E.; Bloy, N.; Castoldi, F.; Abastado, J. P.; Agostinis, P. et al. Classification of current anticancer immunotherapies. Oncotarget 2014, 5, 12472-12508.
[19]
Demaria, O.; Cornen, S.; Daëron, M.; Morel, Y.; Medzhitov, R.; Vivier, E. Harnessing innate immunity in cancer therapy. Nature 2019, 574, 45-56.
[20]
Abril-Rodriguez, G.; Ribas, A. SnapShot: Immune checkpoint inhibitors. Cancer Cell 2017, 31, 848-848.e1.
[21]
Kennedy, L. B.; Salama, A. K. S. A review of cancer immunotherapy toxicity. CA Cancer J. Clin. 2020, 70, 86-104.
[22]
Zhang, H. M.; Chen, J. B. Current status and future directions of cancer immunotherapy. J. Cancer 2018, 9, 1773-1781.
[23]
Sakaguchi, S.; Mikami, N.; Wing, J. B.; Tanaka, A.; Ichiyama, K.; Ohkura, N. Regulatory T cells and human disease. Annu. Rev. Immunol. 2020, 38: 541-566.
[24]
Vinay, D. S.; Ryan, E. P.; Pawelec, G.; Talib, W. H.; Stagg, J.; Elkord, E.; Lichtor, T.; Decker, W. K.; Whelan, R. L.; Kumara, H. M. C. S. et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin. Cancer Biol. 2015, 35, S185-S198.
[25]
Schreiber, R. D.; Old, L. J.; Smyth, M. J. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 2011, 331, 1565-1570.
[26]
Motz, G. T.; Coukos, G. Deciphering and reversing tumor immune suppression. Immunity 2013, 39, 61-73.
[27]
Jensen-Jarolim, E.; Bax, H. J.; Bianchini, R.; Crescioli, S.; Daniels- Wells, T. R.; Dombrowicz, D.; Fiebiger, E.; Gould, H. J.; Irshad, S.; Janda, J. et al. AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer. Allergy 2018, 73, 328-340.
[28]
Makkouk, A.; Weiner, G. J. Cancer immunotherapy and breaking immune tolerance: New approaches to an old challenge. Cancer Res. 2015, 75, 5-10.
[29]
Nishino, M.; Hatabu, H.; Hodi, F. S. Imaging of cancer immunotherapy: Current approaches and future directions. Radiology 2019, 290, 9-22.
[30]
Mulder, W. J. M.; Ochando, J.; Joosten, L. A. B.; Fayad, Z. A.; Netea, M. G. Therapeutic targeting of trained immunity. Nat. Rev. Drug Discov. 2019, 18, 553-566.
[31]
Fan, W. P.; Yung, B.; Huang, P.; Chen, X. Y. Nanotechnology for multimodal synergistic cancer therapy. Chem. Rev. 2017, 117, 13566-13638.
[32]
Russell, L. M.; Liu, C. H.; Grodzinski, P. Nanomaterials innovation as an enabler for effective cancer interventions. Biomaterials 2020, 242, 119926.
[33]
Liu, Y. Y.; Qiao, L. N.; Zhang, S. P.; Wan, G. Y.; Chen, B. W.; Zhou, P.; Zhang, N.; Wang, Y. S. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy. Acta Biomater. 2018, 66, 310-324.
[34]
Desale, S. S.; Raja, S. M.; Kim, J. O.; Mohapatra, B.; Soni, K. S.; Luan, H. T.; Williams, S. H.; Bielecki, T. A.; Feng, D.; Storck, M. et al. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-aag show potent anti-tumor activity in erbb2-driven breast cancer models. J. Control. Release 2015, 208, 59-66.
[35]
Wang, C.; Chen, S. Q.; Wang, Y. X.; Liu, X. R.; Hu, F. Q.; Sun, J. H.; Yuan, H. Lipase-triggered water-responsive “pandora’s box” for cancer therapy: Toward induced neighboring effect and enhanced drug penetration. Adv. Mater. 2018, 30, 1706407.
[36]
Shi, L. L.; Hu, F.; Duan, Y. K.; Wu, W. B.; Dong, J. Q.; Meng, X. J.; Zhu, X. Y.; Liu, B. Hybrid nanospheres to overcome hypoxia and intrinsic oxidative resistance for enhanced photodynamic therapy. ACS Nano 2020, 14, 2183-2190.
[37]
Gulzar, A.; Xu, J. T.; Yang, D.; Xu, L. G.; He, F.; Gai, S. L.; Yang, P. P. Nano-graphene oxide-ucnp-ce6 covalently constructed nanocomposites for nir-mediated bioimaging and ptt/pdt combinatorial therapy. Dalton Trans. 2018, 47, 3931-3939.
[38]
Zhang, C.; Bu, W. B.; Ni, D. L.; Zhang, S. J.; Li, Q.; Yao, Z. W.; Zhang, J. W.; Yao, H. L.; Wang, Z.; Shi, J. L. Synthesis of iron nanometallic glasses and their application in cancer therapy by a localized fenton reaction. Angew. Chem., Int. Ed. 2016, 55, 2101-2106.
[39]
Deepagan, V. G.; You, D. G.; Um, W.; Ko, H.; Kwon, S.; Choi, K. Y.; Yi, G. R.; Lee, J. Y.; Lee, D. S.; Kim, K. et al. Long-circulating au-TiO2 nanocomposite as a sonosensitizer for ros-mediated eradication of cancer. Nano Lett. 2016, 16, 6257-6264.
[40]
Zhu, J. Y.; Zheng, D. W.; Zhang, M. K.; Yu, W. Y.; Qiu, W. X.; Hu, J. J.; Feng, J.; Zhang, X. Z. Preferential cancer cell self-recognition and tumor self-targeting by coating nanoparticles with homotypic cancer cell membranes. Nano Lett. 2016, 16, 5895-5901.
[41]
Cun, X. L.; Ruan, S. B.; Chen, J. T.; Zhang, L.; Li, J. P.; He, Q.; Gao, H. L. A dual strategy to improve the penetration and treatment of breast cancer by combining shrinking nanoparticles with collagen depletion by losartan. Acta Biomater. 2016, 31, 186-196.
[42]
Ma, T. C.; Liu, Y. D.; Wu, Q.; Luo, L. F.; Cui, Y. L.; Wang, X. H.; Chen, X. W.; Tan, L. F.; Meng, X. W. Quercetin-modified metal- organic frameworks for dual sensitization of radiotherapy in tumor tissues by inhibiting the carbonic anhydrase IX. ACS Nano 2019, 13, 4209-4219.
[43]
Wang, J. T. W.; Klippstein, R.; Martincic, M.; Pach, E.; Feldman, R.; Šefl, M.; Michel, Y.; Asker, D.; Sosabowski, J. K.; Kalbac, M. et al. Neutron activated 153Sm sealed in carbon nanocapsules for in vivo imaging and tumor radiotherapy. ACS Nano 2020, 14, 129-141.
[44]
Tavallaie, R.; McCarroll, J.; Le Grand, M.; Ariotti, N.; Schuhmann, W.; Bakker, E.; Tilley, R. D.; Hibbert, D. B.; Kavallaris, M.; Gooding, J. J. Nucleic acid hybridization on an electrically reconfigurable network of gold-coated magnetic nanoparticles enables microrna detection in blood. Nat. Nanotechnol. 2018, 13, 1066-1071.
[45]
Xie, Y.; Hang, Y.; Wang, Y. Z.; Sleightholm, R.; Prajapati, D. R.; Bader, J.; Yu, A.; Tang, W. M.; Jaramillo, L.; Li, J. et al. Stromal modulation and treatment of metastatic pancreatic cancer with local intraperitoneal triple mirna/sirna nanotherapy. ACS Nano 2020, 14, 255-271.
[46]
Wang, S.; Liu, X.; Chen, S. Z.; Liu, Z. R.; Zhang, X. D.; Liang, X. J.; Li, L. L. Regulation of Ca2+ signaling for drug-resistant breast cancer therapy with mesoporous silica nanocapsule encapsulated doxorubicin/sirna cocktail. ACS Nano 2019, 13, 274-283.
[47]
Yang, W. J.; Zhu, G. Z.; Wang, S.; Yu, G. C.; Yang, Z.; Lin, L. S.; Zhou, Z. J.; Liu, Y. J..; Dai, Y. L.; Zhang, F. W. et al. In situ dendritic cell vaccine for effective cancer immunotherapy. ACS Nano 2019, 13, 3083-3094.
[48]
Qiu, F.; Becker, K. W.; Knight, F. C.; Baljon, J. J.; Sevimli, S.; Shae, D.; Gilchuk, P.; Joyce, S.; Wilson, J. T. Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines. Biomaterials 2018, 182, 82-91.
[49]
Gulla, S. K.; Rao, B. R.; Moku, G.; Jinka, S.; Nimmu, N. V.; Khalid, S.; Patra, C. R.; Chaudhuri, A. In vivo targeting of DNA vaccines to dendritic cells using functionalized gold nanoparticles. Biomater. Sci. 2019, 7, 773-788.
[50]
Kranz, L. M.; Diken, M.; Haas, H.; Kreiter, S.; Loquai, C.; Reuter, K. C.; Meng, M.; Fritz, D.; Vascotto, F.; Hefesha, H. et al. Systemic rna delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 2016, 534, 396-401.
[51]
Colzani, B.; Pandolfi, L.; Hoti, A.; Iovene, P. A.; Natalello, A.; Avvakumova, S.; Colombo, M.; Prosperi, D. Investigation of antitumor activities of trastuzumab delivered by plga nanoparticles. Int. J. Nanomedicine 2018, 13, 957-973.
[52]
Shae, D.; Becker, K. W.; Christov, P.; Yun, D. S.; Lytton-Jean, A. K. R.; Sevimli, S.; Ascano, M.; Kelley, M.; Johnson, D. B.; Balko, J. M. et al. Endosomolytic polymersomes increase the activity of cyclic dinucleotide sting agonists to enhance cancer immunotherapy. Nat. Nanotechnol. 2019, 14, 269-278.
[53]
Steeland, S.; Vandenbroucke, R. E.; Libert, C. Nanobodies as therapeutics: Big opportunities for small antibodies. Drug Discov. Today 2016, 21, 1076-1113.
[54]
Song, S. L.; Jin, X. X.; Zhang, L.; Zhao, C.; Ding, Y.; Ang, Q. Q.; Khaidav, O.; Shen, C. L. Pegylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor t-cell responses. Int. J. Nanomedicine 2019, 14, 2465-2483.
[55]
Smith, T. T.; Stephan, S. B.; Moffett, H. F.; McKnight, L. E.; Ji, W. H.; Reiman, D.; Bonagofski, E.; Wohlfahrt, M. E.; Pillai, S. P. S.; Stephan, M. T. In situ programming of leukaemia-specific t cells using synthetic DNA nanocarriers. Nat. Nanotechnol. 2017, 12, 813-820.
[56]
Lang, J. Y.; Zhao, X.; Qi, Y. Q.; Zhang, Y. L.; Han, X. X.; Ding, Y. P.; Guan, J. J.; Ji, T. J.; Zhao, Y.; Nie, G. J. Reshaping prostate tumor microenvironment to suppress metastasis via cancer-associated fibroblast inactivation with peptide-assembly-based nanosystem. ACS Nano 2019, 13, 12357-12371.
[57]
Shen, S.; Li, H. J.; Chen, K. G.; Wang, Y. C.; Yang, X. Z.; Lian, Z. X.; Du, J. Z.; Wang, J. Spatial targeting of tumor-associated macrophages and tumor cells with a pH-sensitive cluster nanocarrier for cancer chemoimmunotherapy. Nano Lett. 2017, 17, 3822-3829.
[58]
Liu, D. C.; Chen, B. L.; Mo, Y. L.; Wang, Z. H.; Qi, T.; Zhang, Q.; Wang, Y. G. Redox-activated porphyrin-based liposome remote-loaded with indoleamine 2,3-dioxygenase (IDO) inhibitor for synergistic photoimmunotherapy through induction of immunogenic cell death and blockage of ido pathway. Nano Lett. 2019, 19, 6964-6976.
[59]
Lang, T. Q.; Liu, Y. R.; Zheng, Z.; Ran, W.; Zhai, Y. H.; Yin, Q.; Zhang, P. C.; Li, Y. P. Cocktail strategy based on spatio-temporally controlled nano device improves therapy of breast cancer. Adv. Mater. 2019, 31, 1806202.
[60]
Gao, S. Q.; Li, T. Y.; Guo, Y.; Sun, C. X.; Xianyu, B. R.; Xu, H. P. Selenium-containing nanoparticles combine the NK cells mediated immunotherapy with radiotherapy and chemotherapy. Adv. Mater. 2020, 32, 1907568.
[61]
Sun, Q. H.; Zhou, Z. X.; Qiu, N. S.; Shen, Y. Q. Rational design of cancer nanomedicine: Nanoproperty integration and synchronization. Adv. Mater. 2017, 29, 1606628.
[62]
Goldberg, M. S. Improving cancer immunotherapy through nanotechnology. Nat. Rev. Cancer 2019, 19, 587-602.
[63]
Zhou, Q.; Shao, S. Q.; Wang, J. Q.; Xu, C. H.; Xiang, J. J.; Piao, Y.; Zhou, Z. X.; Yu, Q. S.; Tang, J. B.; Liu, X. R. et al. Enzyme- activatable polymer-drug conjugate augments tumour penetration and treatment efficacy. Nat. Nanotechnol. 2019, 14, 799-809.
[64]
Zhang, S. Q.; Liu, X.; Sun, Q. X.; Johnson, O.; Yang, T.; Chen, M. L.; Wang, J. H.; Chen, W. Cus@PDA-FA nanocomposites: A dual stimuli-responsive DOX delivery vehicle with ultrahigh loading level for synergistic photothermal-chemotherapies on breast cancer. J. Mater. Chem. B 2020, 8, 1396-1404.
[65]
Zhu, X. H.; Tang, R.; Wang, S. G.; Chen, X. Y.; Hu, J. J.; Lei, C. Y.; Huang, Y.; Wang, H. H.; Nie, Z.; Yao, S. Z. Protein@inorganic nanodumpling system for high-loading protein delivery with activatable fluorescence and magnetic resonance bimodal imaging capabilities. ACS Nano 2020, 14, 2172-2182.
[66]
Kosmides, A. K.; Sidhom, J. W.; Fraser, A.; Bessell, C. A.; Schneck, J. P. Dual targeting nanoparticle stimulates the immune system to inhibit tumor growth. ACS Nano 2017, 11, 5417-5429.
[67]
Yong, T. Y.; Zhang, X. Q.; Bie, N. N.; Zhang, H. B.; Zhang, X. T.; Li, F. Y.; Hakeem, A.; Hu, J.; Gan, L.; Santos, H. A. et al. Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy. Nat. Commun. 2019, 10, 3838.
[68]
He, J. Y.; Li, C. C.; Ding, L.; Huang, Y. N.; Yin, X. L.; Zhang, J. F.; Zhang, J.; Yao, C. J.; Liang, M. M.; Pirraco, R. P. et al. Tumor targeting strategies of smart fluorescent nanoparticles and their applications in cancer diagnosis and treatment. Adv. Mater. 2019, 31, 1902409.
[69]
Wang, X. H.; Wang, X. Y.; Jin, S. X.; Muhammad, N.; Guo, Z. J. Stimuli-responsive therapeutic metallodrugs. Chem. Rev. 2019, 119, 1138-1192.
[70]
Xu, P. P.; Wang, X. Y.; Li, T. W.; Wu, H. H.; Li, L. L.; Chen, Z. L.; Zhang, L.; Guo, Z.; Chen, Q. W. Biomineralization-inspired nanozyme for single-wavelength laser activated photothermal-photodynamic synergistic treatment against hypoxic tumors. Nanoscale 2020, 12, 4051-4060.
[71]
Dasgupta, S.; Rajapakshe, K.; Zhu, B. K.; Nikolai, B. C.; Yi, P.; Putluri, N.; Choi, J. M.; Jung, S. Y.; Coarfa, C.; Westbrook, T. F. et al. Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature 2018, 556, 249-254.
[72]
Gao, R. F.; Li, D.; Xun, J.; Zhou, W.; Li, J.; Wang, J.; Liu, C.; Li, X. R.; Shen, W. Z.; Qiao, H. et al. CD44ICD promotes breast cancer stemness via PFKFB4-mediated glucose metabolism. Theranostics 2018, 8, 6248-6262.
[73]
Sarkar Bhattacharya, S.; Thirusangu, P.; Jin, L.; Roy, D.; Jung, D.; Xiao, Y. N.; Staub, J.; Roy, B.; Molina, J. R.; Shridhar, V. PFKFB3 inhibition reprograms malignant pleural mesothelioma to nutrient stress-induced macropinocytosis and er stress as independent binary adaptive responses. Cell Death Dis. 2019, 10, 725.
[74]
Mondal, S.; Roy, D.; Sarkar Bhattacharya, S.; Jin, L.; Jung, D.; Zhang, S.; Kalogera, E.; Staub, J.; Wang, Y. X.; Xuyang, W. et al. Therapeutic targeting of pfkfb3 with a novel glycolytic inhibitor pfk158 promotes lipophagy and chemosensitivity in gynecologic cancers. Int. J. Cancer 2019, 144, 178-189.
[75]
Li, Y.; He, L. H.; Dong, H. Q.; Liu, Y. Q.; Wang, K.; Li, A.; Ren, T. B.; Shi, D. L.; Li, Y. Y. Fever-inspired immunotherapy based on photothermal cpg nanotherapeutics: The critical role of mild heat in regulating tumor microenvironment. Adv. Sci. 2018, 5, 1700805.
[76]
Hu, X. C.; Lu, Y. L.; Shi, X. K.; Yao, T. M.; Dong, C. Y.; Shi, S. Integrating in situ formation of nanozymes with mesoporous polydopamine for combined chemo, photothermal and hypoxia- overcoming photodynamic therapy. Chem. Commun. 2019, 55, 14785-14788.
[77]
Hu, X. C.; Lu, Y. L.; Dong, C. Y.; Zhao, W. R.; Wu, X. W.; Zhou, L. L.; Chen, L.; Yao, T. M.; Shi, S. A RuII polypyridyl alkyne complex based metal-organic frameworks for combined photodynamic/ photothermal/chemotherapy. Chemistry 2020, 26, 1668-1675.
[78]
Wang, W. Q.; Jin, Y. L.; Xu, Z. A.; Liu, X.; Bajwa, S. Z.; Khan, W. S.; Yu, H. J. Stimuli-activatable nanomedicines for chemodynamic therapy of cancer. Wiley Interdiscip. Rev. Nanomedicine. Nanobiotechnol. 2020, 12, e1614.
[79]
Lin, L. S.; Song, J. B.; Song, L.; Ke, K. M.; Liu, Y. J.; Zhou, Z. J.; Shen, Z. Y.; Li, J.; Yang, Z.; Tang, W. et al. Simultaneous fenton-like ion delivery and glutathione depletion by Mno2-based nanoagent to enhance chemodynamic therapy. Angew. Chem., Int. Ed. 2018, 57, 4902-4906.
[80]
Gao, F. L.; He, G. L.; Yin, H.; Chen, J.; Liu, Y. B.; Lan, C.; Zhang, S. R.; Yang, B. C. Titania-coated 2D gold nanoplates as nanoagents for synergistic photothermal/sonodynamic therapy in the second near- infrared window. Nanoscale 2019, 11, 2374-2384.
[81]
Shen, Z. Y.; Song, J. B.; Zhou, Z. J.; Yung, B. C.; Aronova, M. A.; Li, Y.; Dai, Y. L.; Fan, W. P.; Liu, Y. J.; Li, Z. H. et al. Dotted core-shell nanoparticles for T1 -weighted MRI of tumors. Adv. Mater. 2018, 30, 1803163.
[82]
Liu, Y. J.; Bhattarai, P.; Dai, Z. F.; Chen, X. Y. Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer. Chem. Soc. Rev. 2019, 48, 2053-2108.
[83]
Wong, X. Y.; Sena-Torralba, A.; Álvarez-Diduk, R.; Muthoosamy, K.; Merkoçi, A. Nanomaterials for nanotheranostics: Tuning their properties according to disease needs. ACS Nano 2020, 14, 2585-2627.
[84]
Ali, E. S.; Sharker, S. M.; Islam, M. T.; Khan, I. N.; Shaw, S.; Rahman, M. A.; Uddin, S. J.; Shill, M. C.; Rehman, S.; Das, N. et al. Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives. Semin. Cancer Biol., in press, .
[85]
Wang, S.; Lin, J.; Wang, Z. T.; Zhou, Z. J.; Bai, R. L.; Lu, N.; Liu, Y. J.; Fu, X.; Jacobson, O.; Fan, W. P. et al. Core-satellite polydopamine-gadolinium-metallofullerene nanotheranostics for multimodal imaging guided combination cancer therapy. Adv. Mater. 2017, 29, 1701013.
[86]
Lin, X.; Song, X. F.; Zhang, Y. W.; Cao, Y. B.; Xue, Y. N.; Wu, F. S.; Yu, F. Q.; Wu, M.; Zhu, X. J. Multifunctional theranostic nanosystems enabling photothermal-chemo combination therapy of triple-stimuli- responsive drug release with magnetic resonance imaging. Biomater. Sci. 2020, 8, 1875-1884.
[87]
Yang, Z.; Song, J. B.; Tang, W.; Fan, W. P.; Dai, Y. L.; Shen, Z. Y.; Lin, L. S.; Cheng, S. Y.; Liu, Y. J.; Niu, G. et al. Stimuli-responsive nanotheranostics for real-time monitoring drug release by photoacoustic imaging. Theranostics 2019, 9, 526-536.
[88]
Yang, Z.; Dai, Y. L.; Yin, C.; Fan, Q. L.; Zhang, W. S.; Song, J.; Yu, G. C.; Tang, W.; Fan, W. P.; Yung, B. C. et al. Activatable semiconducting theranostics: Simultaneous generation and ratiometric photoacoustic imaging of reactive oxygen species in vivo. Adv. Mater. 2018, 30, 1707509.
[89]
Sung, Y. C.; Jin, P. R.; Chu, L. A.; Hsu, F. F.; Wang, M. R.; Chang, C. C.; Chiou, S. J.; Qiu, J. T.; Gao, D. Y.; Lin, C. C. et al. Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies. Nat. Nanotechnol. 2019, 14, 1160-1169.
[90]
Truffi, M.; Mazzucchelli, S.; Bonizzi, A.; Sorrentino, L.; Allevi, R.; Vanna, R.; Morasso, C.; Corsi, F. Nano-strategies to target breast cancer-associated fibroblasts: Rearranging the tumor microenvironment to achieve antitumor efficacy. Int. J. Mol. Sci. 2019, 20, 1263.
[91]
Chung, S. J.; Nagaraju, G. P.; Nagalingam, A.; Muniraj, N.; Kuppusamy, P.; Walker, A.; Woo, J.; Győrffy, B.; Gabrielson, E.; Saxena, N. K. et al. ADIPOQ/adiponectin induces cytotoxic autophagy in breast cancer cells through STK11/LKB1-mediated activation of the AMPK-ULK1 axis. Autophagy 2017, 13, 1386-1403.
[92]
Katheder, N. S.; Khezri, R.; O'Farrell, F.; Schultz, S. W.; Jain, A.; Rahman, M. M.; Schink, K. O.; Theodossiou, T. A.; Johansen, T.; Juhász, G. et al. Microenvironmental autophagy promotes tumour growth. Nature 2017, 541, 417-420.
[93]
Chen, Q.; Chen, J. W.; Yang, Z. J.; Xu, J.; Xu, L. G.; Liang, C.; Han, X.; Liu, Z. Nanoparticle-enhanced radiotherapy to trigger robust cancer immunotherapy. Adv. Mater. 2019, 31, 1802228.
[94]
Gao, S.; Zhang, W. Z.; Wang, R. J.; Hopkins, S. P.; Spagnoli, J. C.; Racin, M.; Bai, L.; Li, L.; Jiang, W.; Yang, X. Y. et al. Nanoparticles encapsulating nitrosylated maytansine to enhance radiation therapy. ACS Nano 2020, 14, 1468-1481.
[95]
Sarkar, S.; Levi-Polyachenko, N. Conjugated polymer nano-systems for hyperthermia, imaging and drug delivery. Adv. Drug Deliv. Rev., in press, .
[96]
Hotchkiss, R. D. The quantitative separation of purines, pyrimidines, and nucleosides by paper chromatography. J. Biol. Chem. 1948, 175, 315-332.
[97]
Kubik, T.; Bogunia-Kubik, K.; Sugisaka, M. Nanotechnology on duty in medical applications. Curr. Pharm. Biotechnol. 2005, 6, 17-33.
[98]
Fire, A.; Xu, S. Q.; Montgomery, M. K.; Kostas, S. A.; Driver, S. E.; Mello, C. C. Potent and specific genetic interference by double- stranded rna in Caenorhabditis elegans. Nature 1998, 391, 806-811.
[99]
Yatsunyk, L. A.; Mendoza, O.; Mergny, J. L. “Nano-oddities”: Unusual nucleic acid assemblies for DNA-based nanostructures and nanodevices. Acc. Chem. Res. 2014, 47, 1836-1844.
[100]
Putnam, D. Polymers for gene delivery across length scales. Nat. Mater. 2006, 5, 439-451.
[101]
Xin, Y.; Huang, M.; Guo, W. W.; Huang, Q.; Zhang, L. Z.; Jiang, G. Nano-based delivery of rnai in cancer therapy. Mol. Cancer 2017, 16, 134.
[102]
Liu, Y. J.; Zou, Y.; Feng, C.; Lee, A.; Yin, J. L.; Chung, R.; Park, J. B.; Rizos, H.; Tao, W.; Zheng, M. et al. Charge conversional biomimetic nanocomplexes as a multifunctional platform for boosting orthotopic glioblastoma rnai therapy. Nano Lett. 2020, 20, 1637-1646.
[103]
Yu, T.; Guo, F. F.; Yu, Y. N.; Sun, T. T.; Ma, D.; Han, J. X.; Qian, Y.; Kryczek, I.; Sun, D. F.; Nagarsheth, N. et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 2017, 170, 548-563.e16.
[104]
Eedunuri, V. K.; Rajapakshe, K.; Fiskus, W.; Geng, C. D.; Chew, S. A.; Foley, C.; Shah, S. S.; Shou, J.; Mohamed, J. S.; Coarfa, C. et al. miR-137 targets p160 steroid receptor coactivators SRC1, SRC2, and SRC3 and inhibits cell proliferation. Mol. Endocrinol. 2015, 29, 1170-1183.
[105]
Vodnala, S. K.; Eil, R.; Kishton, R. J.; Sukumar, M.; Yamamoto, T. N.; Ha, N. H.; Lee, P. H.; Shin, M.; Patel, S. J.; Yu, Z. Y. et al. T cell stemness and dysfunction in tumors are triggered by a common mechanism. Science 2019, 363, eaau0135.
[106]
Loginov, V. I.; Burdennyy, A. M.; Pronina, I. V.; Khokonova, V. V.; Kurevljov, S. V.; Kazubskaya, T. P.; Kushlinskii, N. E.; Braga, E. A. Novel miRNA genes hypermethylated in breast cancer. Mol. Biol. 2016, 50, 705-709.
[107]
Zhang, D.; Tang, Z. Y.; Huang, H.; Zhou, G. L.; Cui, C.; Weng, Y. J.; Liu, W. C.; Kim, S.; Lee, S.; Perez-Neut, M. et al. Metabolic regulation of gene expression by histone lactylation. Nature 2019, 574, 575-580.
[108]
Hoos, A. Development of immuno-oncology drugs—from CTLA4 to PD1 to the next generations. Nat. Rev. Drug Discov. 2016, 15, 235-247.
[109]
Dong, H.; Xu, X.; Wang, L. K.; Mo, R. Advances in living cell-based anticancer therapeutics. Biomater. Sci. 2020, 8, 2344-2365.
[110]
Xu, X.; Li, T.; Shen, S. Y.; Wang, J. Q.; Abdou, P.; Gu, Z.; Mo, R. Advances in engineering cells for cancer immunotherapy. Theranostics 2019, 9, 7889-7905.
[111]
Abdou, P.; Wang, Z. J.; Chen, Q.; Chan, A.; Zhou, D. R.; Gunadhi, V.; Gu, Z. Advances in engineering local drug delivery systems for cancer immunotherapy. Wiley Interdiscip. Rev. Nanomedicine. Nanobiotechnol., in press, .
[112]
Sharma, P.; Allison, J. P. The future of immune checkpoint therapy. Science 2015, 348, 56-61.
[113]
Sharma, P.; Allison, J. P. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 2015, 161, 205-214.
[114]
Sang, W.; Zhang, Z.; Dai, Y. L.; Chen, X. Y. Recent advances in nanomaterial-based synergistic combination cancer immunotherapy. Chem. Soc. Rev. 2019, 48, 3771-3810.
[115]
Wei, X. X.; Fong, L.; Small, E. J. Prostate cancer immunotherapy with sipuleucel-T: Current standards and future directions. Expert Rev. Vaccines 2015, 14, 1529-1541.
[116]
Van Der Bruggen, P.; Traversari, C.; Chomez, P.; Lurquin, C.; De Plaen, E.; Van den Eynde, B.; Knuth, A.; Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254, 1643-1647.
[117]
Song, Q.; Zhang, C. D.; Wu, X. H. Therapeutic cancer vaccines: From initial findings to prospects. Immunol. Lett. 2018, 196, 11-21.
[118]
Zhang, Y.; Lin, S. B.; Wang, X. Y.; Zhu, G. Z. Nanovaccines for cancer immunotherapy. Wiley Interdiscip. Rev. Nanomedicine. Nanobiotechnol. 2019, 11, e1559.
[119]
Palucka, K.; Banchereau, J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 2012, 12, 265-277.
[120]
Zhang, J. X.; Mai, J. H.; Li, F.; Shen, J. L.; Zhang, G. D.; Li, J.; Hinkle, L. E.; Lin, D.; Liu, X. W.; Li, Z. et al. Investigation of parameters that determine nano-DC vaccine transport. Biomed. Microdevices 2019, 21, 39.
[121]
Xia, X. J.; Mai, J. H.; Xu, R.; Perez, J. E. T.; Guevara, M. L.; Shen, Q.; Mu, C. F.; Tung, H. Y.; Corry, D. B.; Evans, S. E. et al. Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response. Cell Rep. 2015, 11, 957-966.
[122]
Duong, H. T. T.; Thambi, T.; Yin, Y.; Kim, S. H.; Nguyen, T. L.; Phan, V. H. G.; Kim, J.; Jeong, J. H.; Lee, D. S. Degradation-regulated architecture of injectable smart hydrogels enhances humoral immune response and potentiates antitumor activity in human lung carcinoma. Biomaterials 2020, 230, 119599.
[123]
Milani, A.; Sangiolo, D.; Montemurro, F.; Aglietta, M.; Valabrega, G. Active immunotherapy in HER2 overexpressing breast cancer: Current status and future perspectives. Ann. Oncol. 2013, 24, 1740-1748.
[124]
Yang, Z. G.; Ma, Y. F.; Zhao, H.; Yuan, Y.; Kim, B. Y. S. Nanotechnology platforms for cancer immunotherapy. Wiley Interdiscip. Rev. Nanomedicine. Nanobiotechnol. 2020, 12, e1590.
[125]
Li, A. W.; Sobral, M. C.; Badrinath, S.; Choi, Y.; Graveline, A.; Stafford, A. G.; Weaver, J. C.; Dellacherie, M. O.; Shih, T. Y.; Ali, O. A. et al. A facile approach to enhance antigen response for personalized cancer vaccination. Nat. Mater. 2018, 17, 528-534.
[126]
Wilson, J. T.; Postma, A.; Keller, S.; Convertine, A. J.; Moad, G.; Rizzardo, E.; Meagher, L.; Chiefari, J.; Stayton, P. S. Enhancement of MHC-I antigen presentation via architectural control of pH-responsive, endosomolytic polymer nanoparticles. AAPS J. 2015, 17, 358-369.
[127]
Alspach, E.; Lussier, D. M.; Miceli, A. P.; Kizhvatov, I.; DuPage, M.; Luoma, A. M.; Meng, W.; Lichti, C. F.; Esaulova, E.; Vomund, A. N. et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 2019, 574, 696-701.
[128]
Liu, M. A. DNA vaccines: An historical perspective and view to the future. Immunol. Rev. 2011, 239, 62-84.
[129]
Riley, R. S.; June, C. H.; Langer, R.; Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 2019, 18, 175-196.
[130]
Lu, Y. X.; Wu, F. P.; Duan, W. H.; Mu, X.; Fang, S.; Lu, N. N.; Zhou, X. F.; Kong, W. Engineering a “PEG-g-PEI/DNA nanoparticle-in- PLGA microsphere” hybrid controlled release system to enhance immunogenicity of DNA vaccine. Mater. Sci. Eng. C 2020, 106, 110294.
[131]
Lee, K.; Kim, M.; Seo, Y.; Lee, H. Development of mRNA vaccines and their prophylactic and therapeutic applications. Nano Res. 2018, 11, 5173-5192.
[132]
Li, J. C.; Zhen, X.; Lyu, Y.; Jiang, Y. Y.; Huang, J. G.; Pu, K. Y. Cell membrane coated semiconducting polymer nanoparticles for enhanced multimodal cancer phototheranostics. ACS Nano 2018, 12, 8520-8530.
[133]
Guo, Y. Y.; Wang, D.; Song, Q. L.; Wu, T. T.; Zhuang, X. T.; Bao, Y. L.; Kong, M.; Qi, Y.; Tan, S. W.; Zhang, Z. P. Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma. ACS Nano 2015, 9, 6918-6933.
[134]
Zhou, J. R.; Kroll, A. V.; Holay, M.; Fang, R. H.; Zhang, L. F. Biomimetic nanotechnology toward personalized vaccines. Adv. Mater. 2020, 32, 1901255.
[135]
Hu, Q. Y.; Sun, W. J.; Qian, C. E.; Wang, C.; Bomba, H. N.; Gu, Z. Anticancer platelet-mimicking nanovehicles. Adv. Mater. 2015, 27, 7043-7050.
[136]
Liu, R.; An, Y.; Jia, W. F.; Wang, Y. S.; Wu, Y.; Zhen, Y. H.; Cao, J.; Gao, H. L. Macrophage-mimic shape changeable nanomedicine retained in tumor for multimodal therapy of breast cancer. J. Control. Release 2020, 321, 589-601.
[137]
Gao, C. Y.; Lin, Z. H.; Wu, Z. G.; Lin, X. K.; He, Q. Stem-cell- membrane camouflaging on near-infrared photoactivated upconversion nanoarchitectures for in vivo remote-controlled photodynamic therapy. ACS Appl. Mater. Interfaces 2016, 8, 34252-34260.
[138]
Zou, S. J.; Wang, B. L.; Wang, C.; Wang, Q. Q.; Zhang, L. M. Cell membrane-coated nanoparticles: Research advances. Nanomedicine 2020, 15, 625-641.
[139]
Chen, M. S.; Ouyang, H. C.; Zhou, S. Y.; Li, J. Y.; Ye, Y. B. PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic t cell responses. Cell. Immunol. 2014, 287, 91-99.
[140]
Chen, Q.; Wang, C.; Zhang, X. D.; Chen, G. J.; Hu, Q. Y.; Li, H. J.; Wang, J. Q.; Wen, D.; Zhang, Y. Q.; Lu, Y. F. et al. In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat. Nanotechnol. 2019, 14, 89-97.
[141]
Ma, L. L.; Zhu, M.; Gai, J. W.; Li, G. H.; Chang, Q.; Qiao, P.; Cao, L. L.; Chen, W. Q.; Zhang, S. Y.; Wan, Y. K. Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential. J. Nanobiotechnol. 2020, 18, 12.
[142]
De Bruijn, H. S.; Mashayekhi, V.; Schreurs, T. J. L.; Van Driel, P. B. A. A.; Strijkers, G. J.; Van Diest, P. J.; Lowik, C. W. G. M.; Seynhaeve, A. L. B.; Ten Hagen, T. L. M.; Prompers, J. J. et al. Acute cellular and vascular responses to photodynamic therapy using egfr-targeted nanobody-photosensitizer conjugates studied with intravital optical imaging and magnetic resonance imaging. Theranostics 2020, 10, 2436-2452.
[143]
Hassani, M.; Hajari Taheri, F.; Sharifzadeh, Z.; Arashkia, A.; Hadjati, J.; Van Weerden, W. M.; Abdoli, S.; Modarressi, M. H.; Abolhassani, M. Engineered jurkat cells for targeting prostate-specific membrane antigen on prostate cancer cells by nanobody-based chimeric antigen receptor. Iran. Biomed. J. 2020, 24, 81-88.
[144]
Huang, Y. H.; Zhu, C.; Kondo, Y.; Anderson, A. C.; Gandhi, A.; Russell, A.; Dougan, S. K.; Petersen, B. S.; Melum, E.; Pertel, T. et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 2015, 517, 386-390.
[145]
ElTanbouly, M. A.; Zhao, Y. D.; Nowak, E.; Li, J. N.; Schaafsma, E.; Le Mercier, I.; Ceeraz, S.; Lines, J. L.; Peng, C. W.; Carriere, C. et al. VISTA is a checkpoint regulator for naive T cell quiescence and peripheral tolerance. Science 2020, 367, eaay0524.
[146]
Jafari, S.; Molavi, O.; Kahroba, H.; Hejazi, M. S.; Maleki-Dizaji, N.; Barghi, S.; Kiaie, S. H.; Jadidi-Niaragh, F. Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer. Cell. Mol. Life Sci., in press, .
[147]
Greenwald, R. J.; Freeman, G. J.; Sharpe, A. H. The B7 family revisited. Annu. Rev. Immunol. 2005, 23, 515-548.
[148]
Wei, S. C.; Levine, J. H.; Cogdill, A. P.; Zhao, Y.; Anang, N. A. S.; Andrews, M. C.; Sharma, P.; Wang, J.; Wargo, J. A.; Pe'er, D. et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 2017, 170, 1120-1133.e17.
[149]
Ordikhani, F.; Uehara, M.; Kasinath, V.; Dai, L.; Eskandari, S. K.; Bahmani, B.; Yonar, M.; Azzi, J. R.; Haik, Y.; Sage, P. T. et al. Targeting antigen-presenting cells by anti-PD-1 nanoparticles augments antitumor immunity. JCI Insight 2018, 3, 122700.
[150]
Hu, Q. Y.; Sun, W. J.; Wang, J. Q.; Ruan, H. T.; Zhang, X. D.; Ye, Y. Q.; Shen, S.; Wang, C.; Lu, W. Y.; Cheng, K. et al. Conjugation of haematopoietic stem cells and platelets decorated with anti-pd-1 antibodies augments anti-leukaemia efficacy. Nat. Biomed. Eng. 2018, 2, 831-840.
[151]
Zhu, Y. Y.; An, X.; Zhang, X.; Qiao, Y.; Zheng, T. S.; Li, X. B. STING: A master regulator in the cancer-immunity cycle. Mol. Cancer 2019, 18, 152.
[152]
Luo, M.; Wang, H.; Wang, Z. H.; Cai, H. C.; Lu, Z. G.; Li, Y.; Du, M. J.; Huang, G.; Wang, C. S.; Chen, X. et al. A STING-activating nanovaccine for cancer immunotherapy. Nat. Nanotechnol. 2017, 12, 648-654.
[153]
Ruan, H. T.; Hu, Q. Y.; Wen, D.; Chen, Q.; Chen, G. J.; Lu, Y. F.; Wang, J. Q.; Cheng, H.; Lu, W. Y.; Gu, Z. A dual-bioresponsive drug-delivery depot for combination of epigenetic modulation and immune checkpoint blockade. Adv. Mater. 2019, 31, 1806957.
[154]
Chen, Q.; Wang, C.; Chen, G. J.; Hu, Q. Y.; Gu, Z. Delivery strategies for immune checkpoint blockade. Adv. Healthc. Mater. 2018, 7, 1800424.
[155]
Schmid, P.; Adams, S.; Rugo, H. S.; Schneeweiss, A.; Barrios, C. H.; Iwata, H.; Diéras, V.; Hegg, R.; Im, S. A.; Shaw Wright, G. et al. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 2018, 379, 2108-2121.
[156]
Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Cowey, C. L.; Lao, C. D.; Schadendorf, D.; Dummer, R.; Smylie, M.; Rutkowski, P. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 2015, 373, 23-34.
[157]
Wang, C.; Ye, Y. Q.; Hochu, G. M.; Sadeghifar, H.; Gu, Z. Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody. Nano Lett. 2016, 16, 2334-2340.
[158]
Kuai, R.; Ochyl, L. J.; Bahjat, K. S.; Schwendeman, A.; Moon, J. J. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat. Mater. 2017, 16, 489-496.
[159]
June, C. H.; Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 2018, 379, 64-73.
[160]
Brown, C. E.; Mackall, C. L. CAR T cell therapy: Inroads to response and resistance. Nat. Rev. Immunol. 2019, 19, 73-74.
[161]
Tang, J.; Hubbard-Lucey, V. M.; Pearce, L.; O'Donnell-Tormey, J.; Shalabi, A. The global landscape of cancer cell therapy. Nat. Rev. Drug Discov. 2018, 17, 465-466.
[162]
June, C. H.; O'Connor, R. S.; Kawalekar, O. U.; Ghassemi, S.; Milone, M. C. CAR T cell immunotherapy for human cancer. Science 2018, 359, 1361-1365.
[163]
Hinrichs, C. S.; Rosenberg, S. A. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol. Rev. 2014, 257, 56-71.
[164]
Zhao, L. J.; Cao, Y. J. Engineered T cell therapy for cancer in the clinic. Front. Immunol. 2019, 10, 2250.
[165]
Cheung, A. S.; Zhang, D. K. Y.; Koshy, S. T.; Mooney, D. J. Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells. Nat. Biotechnol. 2018, 36, 160-169.
[166]
Rhodes, K. R.; Green, J. J. Nanoscale artificial antigen presenting cells for cancer immunotherapy. Mol. Immunol. 2018, 98, 13-18.
[167]
Meyer, R. A.; Sunshine, J. C.; Perica, K.; Kosmides, A. K.; Aje, K.; Schneck, J. P.; Green, J. J. Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation. Small 2015, 11, 1519-1525.
[168]
Olden, B. R.; Perez, C. R.; Wilson, A. L.; Cardle, I. I.; Lin, Y. S.; Kaehr, B.; Gustafson, J. A.; Jensen, M. C.; Pun, S. H. Cell-templated silica microparticles with supported lipid bilayers as artificial antigen-presenting cells for T cell activation. Adv. Healthc. Mater. 2019, 8, 1801188.
[169]
Stephan, M. T.; Moon, J. J.; Um, S. H.; Bershteyn, A.; Irvine, D. J. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat. Med. 2010, 16, 1035-1041.
[170]
Stephan, M. T.; Stephan, S. B.; Bak, P.; Chen, J. Z.; Irvine, D. J. Synapse-directed delivery of immunomodulators using T-cell- conjugated nanoparticles. Biomaterials 2012, 33, 5776-5787.
[171]
Huang, B.; Abraham, W. D.; Zheng, Y. R.; Bustamante López, S. C.; Luo, S. S.; Irvine, D. J. Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells. Sci. Transl. Med. 2015, 7, 291ra94.
[172]
Ma, L. Y.; Dichwalkar, T.; Chang, J. Y. H.; Cossette, B.; Garafola, D.; Zhang, A. Q.; Fichter, M.; Wang, C. S.; Liang, S.; Silva, M. et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science 2019, 365, 162-168.
[173]
Chen, Q.; Hu, Q. Y.; Dukhovlinova, E.; Chen, G. J.; Ahn, S.; Wang, C.; Ogunnaike, E. A.; Ligler, F. S.; Dotti, G.; Gu, Z. Photothermal therapy promotes tumor infiltration and antitumor activity of CAR T cells. Adv. Mater. 2019, 31, 1900192.
[174]
Beatty, G. L.; O'Hara, M. H.; Lacey, S. F.; Torigian, D. A.; Nazimuddin, F.; Chen, F.; Kulikovskaya, I. M.; Soulen, M. C.; McGarvey, M.; Nelson, A. M. et al. Activity of mesothelin- specific chimeric antigen receptor t cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology 2018, 155, 29-32.
[175]
Lim, W. A.; June, C. H. The principles of engineering immune cells to treat cancer. Cell 2017, 168, 724-740.
[176]
Millar, D. G.; Ramjiawan, R. R.; Kawaguchi, K.; Gupta, N.; Chen, J.; Zhang, S. F.; Nojiri, T.; Ho, W. W.; Aoki, S.; Jung, K. et al. Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nat. Biotechnol. 2020, 38, 420-425.
[177]
Thakkar, S.; Sharma, D.; Kalia, K.; Tekade, R. K. Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: A review. Acta Biomater. 2020, 101, 43-68.
[178]
Chen, Q.; Liu, G. X.; Liu, S.; Su, H. Y.; Wang, Y.; Li, J. Y.; Luo, C. Remodeling the tumor microenvironment with emerging nanotherapeutics. Trends Pharmacol. Sci. 2018, 39, 59-74.
[179]
Sahai, E.; Astsaturov, I.; Cukierman, E.; DeNardo, D. G.; Egeblad, M.; Evans, R. M.; Fearon, D.; Greten, F. R.; Hingorani, S. R.; Hunter, T. et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer 2020, 20, 174-186.
[180]
Fukumura, D.; Xavier, R.; Sugiura, T.; Chen, Y.; Park, E. C.; Lu, N. F.; Selig, M.; Nielsen, G.; Taksir, T.; Jain, R. K. et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998, 94, 715-725.
[181]
Bhome, R.; Goh, R. W.; Bullock, M. D.; Pillar, N.; Thirdborough, S. M.; Mellone, M.; Mirnezami, R.; Galea, D.; Veselkov, K.; Gu, Q. et al. Exosomal microRNAs derived from colorectal cancer- associated fibroblasts: Role in driving cancer progression. Aging 2017, 9, 2666-2694.
[182]
Kojima, Y.; Acar, A.; Eaton, E. N.; Mellody, K. T.; Scheel, C.; Ben-Porath, I.; Onder, T. T.; Wang, Z. C.; Richardson, A. L.; Weinberg, R. A. et al. Autocrine TGF-β and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc. Natl. Acad. Sci. USA 2010, 107, 20009-20014.
[183]
Hou, L.; Liu, Q.; Shen, L. M.; Liu, Y.; Zhang, X. Q.; Chen, F. Q.; Huang, L. Nano-delivery of fraxinellone remodels tumor microenvironment and facilitates therapeutic vaccination in desmoplastic melanoma. Theranostics 2018, 8, 3781-3796.
[184]
Hu, C. H.; Liu, X. Y.; Ran, W.; Meng, J.; Zhai, Y. H.; Zhang, P. C.; Yin, Q.; Yu, H. J.; Zhang, Z. W.; Li, Y. P. Regulating cancer associated fibroblasts with losartan-loaded injectable peptide hydrogel to potentiate chemotherapy in inhibiting growth and lung metastasis of triple negative breast cancer. Biomaterials 2017, 144, 60-72.
[185]
Zhang, B.; Jin, K.; Jiang, T.; Wang, L. T.; Shen, S.; Luo, Z. M.; Tuo, Y. Y.; Liu, X. P.; Hu, Y.; Pang, Z. Q. Celecoxib normalizes the tumor microenvironment and enhances small nanotherapeutics delivery to A549 tumors in nude mice. Sci. Rep. 2017, 7, 10071.
[186]
Li, W.; Zhao, X. X.; Du, B.; Li, X.; Liu, S. H.; Yang, X. Y.; Ding, H.; Yang, W. D.; Pan, F.; Wu, X. B. et al. Gold nanoparticle-mediated targeted delivery of recombinant human endostatin normalizes tumour vasculature and improves cancer therapy. Sci. Rep. 2016, 6, 30619.
[187]
Lewis, C. E.; Pollard, J. W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66, 605-612.
[188]
Ngambenjawong, C.; Gustafson, H. H.; Pun, S. H. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv. Drug Deliv. Rev. 2017, 114, 206-221.
[189]
Okabe, Y.; Medzhitov, R. Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell 2014, 157, 832-844.
[190]
Gordon, S.; Martinez, F. O. Alternative activation of macrophages: Mechanism and functions. Immunity 2010, 32, 593-604.
[191]
Rodell, C. B.; Arlauckas, S. P.; Cuccarese, M. F.; Garris, C. S.; Li, R.; Ahmed, M. S.; Kohler, R. H.; Pittet, M. J.; Weissleder, R. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat. Biomed. Eng. 2018, 2, 578-588.
[192]
Chen, L.; Zhou, L. L.; Wang, C. H.; Han, Y.; Lu, Y. L.; Liu, J.; Hu, X. C.; Yao, T. M.; Lin, Y.; Liang, S. J. et al. Tumor-targeted drug and CpG delivery system for phototherapy and docetaxel-enhanced immunotherapy with polarization toward M1-type macrophages on triple negative breast cancers. Adv. Mater. 2019, 31, 1904997.
[193]
Tsai, S. J.; Andorko, J. I.; Zeng, X. B.; Gammon, J. M.; Jewell, C. M. Polyplex interaction strength as a driver of potency during cancer immunotherapy. Nano Res. 2018, 11, 5642-5656.
[194]
Kim, S. Y.; Kim, S.; Kim, J. E.; Lee, S. N.; Shin, I. W.; Shin, H. S.; Jin, S. M.; Noh, Y. W.; Kang, Y. J.; Kim, Y. S. et al. Lyophilizable and multifaceted toll-like receptor 7/8 agonist-loaded nanoemulsion for the reprogramming of tumor microenvironments and enhanced cancer immunotherapy. ACS Nano 2019, 13, 12671-12686.
[195]
Cheng, N.; Watkins-Schulz, R.; Junkins, R. D.; David, C. N.; Johnson, B. M.; Montgomery, S. A.; Peine, K. J.; Darr, D. B.; Yuan, H.; McKinnon, K. P. et al. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer. JCI Insight 2018, 3, e120638.
[196]
Conde, J.; Bao, C. C.; Tan, Y. Q.; Cui, D. X.; Edelman, E. R.; Azevedo, H. S.; Byrne, H. J.; Artzi, N.; Tian, F. R. Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumor-associated macrophages and cancer cells. Adv. Funct. Mater. 2015, 25, 4183-4194.
[197]
Ma, S.; Song, W. T.; Xu, Y. D.; Si, X. H.; Zhang, D. W.; Lv, S. X.; Yang, C. G.; Ma, L. L.; Tang, Z. H.; Chen, X. S. Neutralizing tumor-promoting inflammation with polypeptide-dexamethasone conjugate for microenvironment modulation and colorectal cancer therapy. Biomaterials 2020, 232, 119676.
[198]
Colegio, O. R.; Chu, N. Q.; Szabo, A. L.; Chu, T.; Rhebergen, A. M.; Jairam, V.; Cyrus, N.; Brokowski, C. E.; Eisenbarth, S. C.; Phillips, G. M. et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 2014, 513, 559-563.
[199]
Saeed, M.; Gao, J.; Shi, Y.; Lammers, T.; Yu, H. J. Engineering nanoparticles to reprogram the tumor immune microenvironment for improved cancer immunotherapy. Theranostics 2019, 9, 7981-8000.
[200]
Takikawa, O. Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. Biochem. Biophys. Res. Commun. 2005, 338, 12-19.
[201]
Guzik, K.; Tomala, M.; Muszak, D.; Konieczny, M.; Hec, A.; Blaszkiewicz, U.; Pustula, M.; Butera, R.; Dömling, A.; Holak, T. A. Development of the inhibitors that target the PD-1/PD-L1 interaction—a brief look at progress on small molecules, peptides and macrocycles. Molecules 2019, 24, 2071.
[202]
Shi, D. F.; An, X. L.; Bai, Q. F.; Bing, Z. T.; Zhou, S. Y.; Liu, H. X.; Yao, X. J. Computational insight into the small molecule intervening PD-L1 dimerization and the potential structure-activity relationship. Front. Chem. 2019, 7, 764.
[203]
Skalniak, L.; Zak, K. M.; Guzik, K.; Magiera, K.; Musielak, B.; Pachota, M.; Szelazek, B.; Kocik, J.; Grudnik, P.; Tomala, M. et al. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget 2017, 8, 72167-72181.
[204]
Sasikumar, P. G.; Ramachandra, R. K.; Adurthi, S.; Dhudashiya, A. A.; Vadlamani, S.; Vemula, K.; Vunnum, S.; Satyam, L. K.; Samiulla, D. S.; Subbarao, K. et al. A rationally designed peptide antagonist of the PD-1 signaling pathway as an immunomodulatory agent for cancer therapy. Mol. Cancer Ther. 2019, 18, 1081-1091.
[205]
Musielak, B.; Kocik, J.; Skalniak, L.; Magiera-Mularz, K.; Sala, D.; Czub, M.; Stec, M.; Siedlar, M.; Holak, T. A.; Plewka, J. CA-170-a potent small-molecule PD-L1 inhibitor or not? Molecules 2019, 24, 2804.
[206]
Li, C. L.; Zhang, N. P.; Zhou, J. D.; Ding, C.; Jin, Y. Q.; Cui, X. Y.; Pu, K. F.; Zhu, Y. M. Peptide blocking of PD-1/PD-L1 interaction for cancer immunotherapy. Cancer Immunol. Res. 2018, 6, 178-188.
[207]
Qian, Y.; Qiao, S.; Dai, Y. F.; Xu, G. Q.; Dai, B. L.; Lu, L. S.; Yu, X.; Luo, Q. M.; Zhang, Z. H. Molecular-targeted immunotherapeutic strategy for melanoma via dual-targeting nanoparticles delivering small interfering RNA to tumor-associated macrophages. ACS Nano 2017, 11, 9536-9549.